HopeStage
Back to all studies
SuspendedNCT03513549

Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolarity type I

Observational studyAges 18+United States
The study in practice

Understand this study

Who could participate?

Listed age limits: from 18 years.

Listed locations
RaleighSee all locations and recruitment

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: November 4, 2014
Recruitment status
Suspended
Enrollment listed in the registry
10,000
Sponsor
Alexza Pharmaceuticals, Inc.
Sponsor type
Other organization
Study type
Observational
Intervention type
Drug
Locations
United States
Age range
Over 18 Years
Official registry ID
NCT03513549
Official title
Show the full official title

A Postmarketing Observational Study to Evaluate the Safety of ADASUVE® (STACCATO® Loxapine for Inhalation) in Patients With Agitation Associated With Schizophrenia or Bipolar I Disorder

Recruitment & locations

Suspended

Raleigh

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Alexza Pharmaceuticals, Inc.

Does this study involve medication?

Yes. The study involves medication, including Loxapine 10 MG.

Who can participate?

Listed age limits: from 18 years.

Is this study still recruiting?

The registry lists this study as suspended.

Want to explore more studies?

Explore studies